UNSPSC 51202807: Zotarolimus

This classification denotes an immunosuppressant with the molecular formula C52H79N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H4GXR80IZE, chemically known as (42s)-42-deoxy-42-(1h-tetrazol-1-yl)-rapamycin but more generally known as zotarolimus, which bears US NIH Compound Identifier 9876378. European Medicines Agency schedules zotarolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32090.

UNSPSC 51202807 Zotarolimus is a Commodity code designating a specific pharmaceutical active ingredient, but the recent state and local opportunities posted under this code do not reflect procurement of zotarolimus itself. Instead, the posted records show state and local agencies soliciting unrelated pharmaceutical products — antibiotic tablets through a piggyback warehouse contract and naloxone with drug deactivation systems through a direct competitive bid. This mismatch suggests either a tagging error in the opportunities block or limited current activity aligned with the zotarolimus commodity designation. The scope of work nominally covers zotarolimus, a drug-eluting stent coating used in interventional cardiology, but recent procurement activity under the code does not bear this out.

The geographic footprint reflected in posted opportunities spans Illinois and Florida, with the Illinois Department of Public Health executing a completed $2,999,999.11 piggyback pharmaceutical warehouse award to Chartwell Rx LLC on August 28, 2026 (awarded under IFB through the MMCAP Infuse consortium), and Seminole County, Florida releasing a competitive bid for naloxone and drug deactivation systems with a July 26, 2023 response deadline. No active open solicitations for zotarolimus or closely related pharmaceutical products appear in the recent opportunities block. Firms should verify code assignment with issuing bodies before pursuing opportunities tagged under 51202807, as the current posting record does not reflect consistent procurement of the zotarolimus commodity itself.